INFLECTRA

INFLECTRA (infliximab-dyyb) for Injection, for Intravenous Use
INFLECTRA (infliximab-dyyb) is biosimilar* to REMICADE (infliximab) for the indications listed.

Pfizer

1.1 Crohn’s Disease
INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.
INFLECTRA is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease.

1.2 Pediatric Crohn’s Disease
INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.

1.3 Ulcerative Colitis
INFLECTRA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

1.4 Rheumatoid Arthritis
INFLECTRA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

1.5 Ankylosing Spondylitis
INFLECTRA is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

1.6 Psoriatic Arthritis
INFLECTRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.

1.7 Plaque Psoriasis
INFLECTRA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. INFLECTRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning, Warnings and Precautions.

INFLECTRA must be refrigerated at 2ºC to 8ºC (36ºF to 46ºF). Do not use INFLECTRA beyond the expiration date (Exp) located on the carton and the vial. This product contains no preservative.